Department of General Practice, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Department of Medical, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Medicine (Baltimore). 2021 Jul 2;100(26):e26422. doi: 10.1097/MD.0000000000026422.
Probiotics supplementation has emerged as adjuvant therapy for chronic kidney disease (CKD) in recent years. However, the effects of probiotic preparations on serum inflammatory cytokine levels are still highly controversial and poorly documented. Therefore, we performed the protocol for systematic review and meta-analysis to further clarify the effects of probiotic preparations in CKD patients.
This review will develop following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. We searched literature published until May, 2021 thoroughly in PUBMED, Scopus, EMBASE, Web of Science, and Cochrane Library databases on May, 2021. The risk of bias of included studies was estimated by taking into consideration the characteristics including random sequence generation, allocation concealment, blinding of patients, blinding of outcome assessment, completeness of outcome data, selective reporting, and other bias by Cochrane Collaboration's tool for assessing the risk of bias. Data synthesis and analyses were performed using Stata version 10.0 software.
The results of this systematic review and meta-analysis will be published in a peer-reviewed journal.
We hypothesized that probiotic preparations may decrease the serum levels of inflammatory cytokines and protect the intestinal epithelial barrier of patients with CKD.
近年来，益生菌补充剂已成为慢性肾脏病（CKD）的辅助治疗方法。然而，益生菌制剂对血清炎症细胞因子水平的影响仍存在很大争议，且相关证据不足。因此，我们制定了系统评价和荟萃分析的方案，以进一步阐明益生菌制剂在 CKD 患者中的作用。
本综述将遵循系统评价和荟萃分析的首选报告项目声明指南进行。我们于 2021 年 5 月在 PUBMED、Scopus、EMBASE、Web of Science 和 Cochrane Library 数据库中全面检索了截至 2021 年 5 月发表的文献。通过考虑随机序列生成、分配隐藏、患者盲法、结局评估盲法、结局数据完整性、选择性报告以及 Cochrane 协作工具评估的其他偏倚等特征，评估纳入研究的偏倚风险。使用 Stata 版本 10.0 软件进行数据综合和分析。
本系统评价和荟萃分析的结果将发表在同行评议的期刊上。
我们假设益生菌制剂可能降低 CKD 患者的血清炎症细胞因子水平，并保护其肠道上皮屏障。
